PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment

BackgroundDespite the notable success of programmed death ligand 1 (PD-L1)/programmed death 1 (PD-1) immune checkpoint blockade in cancer, resistance remains a substantial challenge. Combining immune checkpoint blockade with direct targeting of effector T cells to tumor cells might improve outcome f...

Full description

Saved in:

Bibliographic Details
Published in:	Journal for immunotherapy of cancer Vol. 13; no. 10; p. e012255
Main Authors:	King, Lisa A, Veth, Myrthe, Roos, Marieke, Scheffer, George L, Popovic, Marko A, de Gruijl, Tanja D, van der Vliet, Hans J
Format:	Journal Article
Language:	English
Published:	England BMJ Publishing Group Ltd 29.10.2025 BMJ Publishing Group LTD BMJ Publishing Group
Subjects:	Antibodies Antibodies, Bispecific - pharmacology Antibody Antigen presentation B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - immunology B7-H1 Antigen - metabolism Basic and translational cancer immunology Cell Line, Tumor Chromatography Cloning Cytokines Flow cytometry Humans Immune Checkpoint Inhibitor Immune checkpoint inhibitors Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immune response Immunotherapy Ligands Lymphocytes Melanoma Programmed Cell Death 1 Receptor - antagonists & inhibitors Proteins Solid tumor T cell T cell receptors Tumor Microenvironment - drug effects Tumor Microenvironment - immunology Tumor microenvironment - TME Tumor necrosis factor-TNF United States > US Solid tumor Immune Checkpoint Inhibitor Antibody Tumor microenvironment - TME T cell
ISSN:	2051-1426, 2051-1426
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!